Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

F. Lo-Coco, G. Avvisati, M. Vignetti, C. Thiede, S. M. Orlando, S. Iacobelli, F. Ferrara, P. Fazi, L. Cicconi, E. Di Bona, G. Specchia, Simona Sica, M. Divona, A. Levis, W. Fiedler, E. Cerqui, M. Breccia, G. Fioritoni, H. R. Salih, M. CazzolaL. Melillo, A. M. Carella, C. H. Brandts, E. Morra, M. Von Lilienfeld-Toal, B. Hertenstein, M. Wattad, M. Lübbert, M. Hänel, N. Schmitz, H. Link, M. G. Kropp, A. Rambaldi, G. La Nasa, M. Luppi, F. Ciceri, O. Finizio, A. Venditti, F. Fabbiano, K. Döhner, M. Sauer, A. Ganser, S. Amadori, F. Mandelli, H. Döhner, G. Ehninger, R. F. Schlenk, U. Platzbecker

Research output: Contribution to journalArticle

819 Citations (Scopus)


All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity.
Original languageEnglish
Pages (from-to)111-121
Number of pages11
JournalNew England Journal of Medicine
Publication statusPublished - 2013


  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Arsenicals
  • Consolidation Chemotherapy
  • Disease-Free Survival
  • Female
  • Humans
  • Induction Chemotherapy
  • Leukemia, Promyelocytic, Acute
  • Maintenance Chemotherapy
  • Male
  • Middle Aged
  • Neutropenia
  • Oxides
  • Thrombocytopenia
  • Tretinoin
  • Young Adult


Dive into the research topics of 'Retinoic acid and arsenic trioxide for acute promyelocytic leukemia'. Together they form a unique fingerprint.

Cite this